CLINICAL_TRIALS ClinicalTrials.gov record update

Impact of a Centralized Tumour Board on Secondary Intervention Rate in Patients With RAS Mutant Metastatic Colorectal Cancer After First-line Treatment With FOLFOXIRI Plus Bevacizumab (FIRE-7)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04852250
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:13.293174+00:00
Published At: 2021-04-21T00:00:00+00:00
Record Updated At: 2021-04-21
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Colorectal Cancer", "RAS Mutation", "Multidisciplinary Communication", "Secondary Intervention"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-04-21"
protocolSection.identificationModule.nctId: "NCT04852250"
protocolSection.identificationModule.officialTitle: "Impact of a Centralized Tumour Board on Secondary Intervention Rate in Patients With RAS Mutant Metastatic Colorectal Cancer After First-line Treatment With FOLFOXIRI Plus Bevacizumab (FIRE-7)"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.